000128067 001__ 128067
000128067 005__ 20240228145532.0
000128067 0247_ $$2doi$$a10.1038/bmt.2017.91
000128067 0247_ $$2pmid$$apmid:28504661
000128067 0247_ $$2pmc$$apmc:PMC5543255
000128067 0247_ $$2ISSN$$a0268-3369
000128067 0247_ $$2ISSN$$a0951-3078
000128067 0247_ $$2ISSN$$a1476-5365
000128067 0247_ $$2altmetric$$aaltmetric:20165397
000128067 037__ $$aDKFZ-2017-04089
000128067 041__ $$aeng
000128067 082__ $$a610
000128067 1001_ $$aHuhn, S.$$b0
000128067 245__ $$aCirculating tumor cells as a biomarker for response to therapy in multiple myeloma patients treated within the GMMG-MM5 trial.
000128067 260__ $$aLondon$$bNature Publishing Group55086$$c2017
000128067 264_1 $$2Crossref$$3online$$bSpringer Science and Business Media LLC$$c2017-05-15
000128067 264_1 $$2Crossref$$3print$$bSpringer Science and Business Media LLC$$c2017-08-01
000128067 264_1 $$2Crossref$$3print$$bSpringer Science and Business Media LLC$$c2017-08-01
000128067 3367_ $$2DRIVER$$aarticle
000128067 3367_ $$2DataCite$$aOutput Types/Journal article
000128067 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1510664536_10758
000128067 3367_ $$2BibTeX$$aARTICLE
000128067 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000128067 3367_ $$00$$2EndNote$$aJournal Article
000128067 536__ $$0G:(DE-HGF)POF3-319H$$a319H - Addenda (POF3-319H)$$cPOF3-319H$$fPOF III$$x0
000128067 542__ $$2Crossref$$i2017-05-15$$uhttps://creativecommons.org/licenses/by-nc-nd/4.0
000128067 588__ $$aDataset connected to CrossRef, PubMed,
000128067 7001_ $$aWeinhold, N.$$b1
000128067 7001_ $$aNickel, J.$$b2
000128067 7001_ $$aPritsch, M.$$b3
000128067 7001_ $$0P:(DE-He78)743a4a82daab55306a2c88b9f6bf8c2f$$aHielscher, T.$$b4
000128067 7001_ $$0P:(DE-He78)fae4f3c76bbbd2fc21dd920b46945d42$$aHummel, M.$$b5
000128067 7001_ $$aBertsch, U.$$b6
000128067 7001_ $$aHuegle-Doerr, B.$$b7
000128067 7001_ $$aVogel, M.$$b8
000128067 7001_ $$aAngermund, R.$$b9
000128067 7001_ $$aHänel, M.$$b10
000128067 7001_ $$aSalwender, H. J.$$b11
000128067 7001_ $$aWeisel, K.$$b12
000128067 7001_ $$aDürig, J.$$b13
000128067 7001_ $$aGörner, M.$$b14
000128067 7001_ $$aKirchner, H.$$b15
000128067 7001_ $$aPeter, N.$$b16
000128067 7001_ $$aGraeven, U.$$b17
000128067 7001_ $$aLordick, F.$$b18
000128067 7001_ $$aHoffmann, M.$$b19
000128067 7001_ $$aReimer, P.$$b20
000128067 7001_ $$aBlau, I. W.$$b21
000128067 7001_ $$aJauch, A.$$b22
000128067 7001_ $$aDembowsky, K.$$b23
000128067 7001_ $$aMöhler, T.$$b24
000128067 7001_ $$aWuchter, P.$$b25
000128067 7001_ $$0P:(DE-He78)a1aa959d47e3e026abe157a8adf24b96$$aGoldschmidt, H.$$b26$$udkfz
000128067 77318 $$2Crossref$$3journal-article$$a10.1038/bmt.2017.91$$bSpringer Science and Business Media LLC$$d2017-05-15$$n8$$p1194-1198$$tBone Marrow Transplantation$$v52$$x0268-3369$$y2017
000128067 773__ $$0PERI:(DE-600)2004030-1$$a10.1038/bmt.2017.91$$gVol. 52, no. 8, p. 1194 - 1198$$n8$$p1194-1198$$tBone marrow transplantation$$v52$$x0268-3369$$y2017
000128067 909CO $$ooai:inrepo02.dkfz.de:128067$$pVDB
000128067 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)743a4a82daab55306a2c88b9f6bf8c2f$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000128067 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)fae4f3c76bbbd2fc21dd920b46945d42$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000128067 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a1aa959d47e3e026abe157a8adf24b96$$aDeutsches Krebsforschungszentrum$$b26$$kDKFZ
000128067 9131_ $$0G:(DE-HGF)POF3-319H$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vAddenda$$x0
000128067 9141_ $$y2017
000128067 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000128067 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000128067 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bBONE MARROW TRANSPL : 2014
000128067 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000128067 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000128067 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000128067 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000128067 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000128067 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000128067 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000128067 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000128067 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000128067 9201_ $$0I:(DE-He78)C060-20160331$$kC060$$lBiostatistik$$x0
000128067 9201_ $$0I:(DE-He78)V964-20160331$$kV964$$lNCT-KliHD$$x1
000128067 980__ $$ajournal
000128067 980__ $$aVDB
000128067 980__ $$aI:(DE-He78)C060-20160331
000128067 980__ $$aI:(DE-He78)V964-20160331
000128067 980__ $$aUNRESTRICTED
000128067 999C5 $$1SK Kumar$$2Crossref$$9-- missing cx lookup --$$a10.1038/leu.2013.313$$p1122 -$$tLeukemia$$uKumar SK, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Pandey S et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia 2014; 28: 1122–1128.$$v28$$y2014
000128067 999C5 $$1S Kumar$$2Crossref$$9-- missing cx lookup --$$a10.1016/S1470-2045(16)30206-6$$pe328 -$$tLancet Oncol$$uKumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol 2016; 17: e328–e346.$$v17$$y2016
000128067 999C5 $$1H Avet-Loiseau$$2Crossref$$9-- missing cx lookup --$$a10.1182/blood.V126.23.191.191$$p191 -$$tBlood$$uAvet-Loiseau H, Corre J, Lauwers-Cances V, Chretien M-L, Robillard N, Leleu X et al. Evaluation of minimal residual disease (MRD) by next generation sequencing (NGS) is highly predictive of progression free survival in the IFM/DFCI 2009 Trial. Blood 2015; 126: 191.$$v126$$y2015
000128067 999C5 $$1AC Rawstron$$2Crossref$$9-- missing cx lookup --$$a10.1200/JCO.2012.46.2119$$p2540 -$$tJ Clin Oncol$$uRawstron AC, Child JA, de Tute RM, Davies FE, Gregory WM, Bell SE et al. Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX Study. J Clin Oncol 2013; 31: 2540–2547.$$v31$$y2013
000128067 999C5 $$1AM Sherrod$$2Crossref$$9-- missing cx lookup --$$a10.1038/bmt.2015.164$$p2 -$$tBone Marrow Transplant$$uSherrod AM, Hari P, Mosse CA, Walker RC, Cornell RF . Minimal residual disease testing after stem cell transplantation for multiple myeloma. Bone Marrow Transplant 2016; 51: 2–12.$$v51$$y2016
000128067 999C5 $$1EK Mai$$2Crossref$$9-- missing cx lookup --$$a10.1038/leu.2015.80$$p1721 -$$tLeukemia$$uMai EK, Bertsch U, Durig J, Kunz C, Haenel M, Blau IW et al. Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myeloma. Leukemia 2015; 29: 1721–1729.$$v29$$y2015
000128067 999C5 $$1P Sonneveld$$2Crossref$$9-- missing cx lookup --$$a10.1200/JCO.2011.39.6820$$p2946 -$$tJ Clin Oncol$$uSonneveld P, Schmidt-Wolf IG, van der Holt B, El Jarari L, Bertsch U, Salwender H et al. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial. J Clin Oncol 2012; 30: 2946–2955.$$v30$$y2012
000128067 999C5 $$1FW Cremer$$2Crossref$$9-- missing cx lookup --$$a10.1023/A:1008286803199$$p633 -$$tAnn Oncol$$uCremer FW, Kiel K, Wallmeier M, Goldschmidt H, Moos M . A quantitative PCR assay for the detection of low amounts of malignant cells in multiple myeloma. Ann Oncol 1997; 8: 633–636.$$v8$$y1997
000128067 999C5 $$1Y Hu$$2Crossref$$9-- missing cx lookup --$$a10.1016/j.jim.2009.06.008$$p70 -$$tJ Immunol Methods$$uHu Y, Smyth GK . ELDA: extreme limiting dilution analysis for comparing depleted and enriched populations in stem cell and other assays. J Immunol Methods 2009; 347: 70–78.$$v347$$y2009
000128067 999C5 $$2Crossref$$uHelsel DR. Nondetects and Data Analysis: Statistics for Censored Environmental Data. John Wiley and Sons: Hoboken, NJ, USA, 2005..
000128067 999C5 $$1PR Greipp$$2Crossref$$9-- missing cx lookup --$$a10.1200/JCO.2005.04.242$$p3412 -$$tJ Clin Oncol$$uGreipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Blade J et al. International staging system for multiple myeloma. J Clin Oncol 2005; 23: 3412–3420.$$v23$$y2005
000128067 999C5 $$1K Neben$$2Crossref$$9-- missing cx lookup --$$a10.3324/haematol.2009.016436$$p1150 -$$tHaematologica$$uNeben K, Jauch A, Bertsch U, Heiss C, Hielscher T, Seckinger A et al. Combining information regarding chromosomal aberrations t(4;14) and del(17p13) with the International Staging System classification allows stratification of myeloma patients undergoing autologous stem cell transplantation. Haematologica 2010; 95: 1150–1157.$$v95$$y2010
000128067 999C5 $$1K Neben$$2Crossref$$9-- missing cx lookup --$$a10.1182/blood-2011-09-379164$$p940 -$$tBlood$$uNeben K, Lokhorst HM, Jauch A, Bertsch U, Hielscher T, van der Holt B et al. Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p. Blood 2012; 119: 940–948.$$v119$$y2012
000128067 999C5 $$1O Landgren$$2Crossref$$9-- missing cx lookup --$$a10.1002/cyto.b.21273$$p14 -$$tCytometry B Clin Cytom$$uLandgren O, Owen RG . Better therapy requires better response evaluation: paving the way for minimal residual disease testing for every myeloma patient. Cytometry B Clin Cytom 2016; 90: 14–20.$$v90$$y2016
000128067 999C5 $$1S Mailankody$$2Crossref$$9-- missing cx lookup --$$a10.1038/nrclinonc.2014.239$$p286 -$$tNat Rev Clin Oncol$$uMailankody S, Korde N, Lesokhin AM, Lendvai N, Hassoun H, Stetler-Stevenson M et al. Minimal residual disease in multiple myeloma: bringing the bench to the bedside. Nat Rev Clin Oncol 2015; 12: 286–295.$$v12$$y2015